Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Proteolysis targeting chimera (PROTAC) technology offers a novel therapeutic strategy in drug discovery.
• PROTACs are heterobifunctional molecules that recruit target proteins to E3 ligases for degradation.
• Anaplastic lymphoma kinase (ALK) fusion proteins are key oncogenic drivers in certain cancers.

Purpose of the Study:

• To develop and evaluate novel PROTAC molecules targeting ALK fusion proteins.
• To assess the efficacy of these ALK-PROTACs in degrading ALK and inhibiting cancer cell growth.
• To investigate the therapeutic potential of ALK-PROTACs in preclinical cancer models.

Main Methods:

• Design and synthesis of ALK-PROTACs incorporating ceritinib and VHL E3 ligase ligand.
• Evaluation of ALK degradation and inhibition of cell proliferation in ALK fusion-positive cell lines (SU-DHL-1, H3122).
• Assessment of tumor growth inhibition in a H3122 xenograft mouse model.

Main Results:

• The ALK-PROTAC molecule TD-004 demonstrated effective degradation of ALK fusion proteins.
• TD-004 significantly inhibited the growth of SU-DHL-1 and H3122 cell lines.
• TD-004 treatment resulted in a significant reduction in tumor growth in the H3122 xenograft model.

Conclusions:

• TD-004 is a potent ALK-PROTAC capable of inducing target degradation and inhibiting cancer cell proliferation.
• These findings highlight the therapeutic potential of ALK-PROTACs for treating cancers driven by ALK fusions.
• PROTAC technology represents a promising approach for targeted protein degradation in oncology.